ES2660157T3 - Tratamiento de la mucositis con inmunoglobulina A - Google Patents

Tratamiento de la mucositis con inmunoglobulina A Download PDF

Info

Publication number
ES2660157T3
ES2660157T3 ES13708170.9T ES13708170T ES2660157T3 ES 2660157 T3 ES2660157 T3 ES 2660157T3 ES 13708170 T ES13708170 T ES 13708170T ES 2660157 T3 ES2660157 T3 ES 2660157T3
Authority
ES
Spain
Prior art keywords
composition
use according
mucositis
iga
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13708170.9T
Other languages
English (en)
Spanish (es)
Inventor
Christoph Aebi
Sonja Christina Lueer
Alexander Schaub
Sylvia Miescher
Adrian Zuercher
Cédric Pierre VONARBURG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
CSL Behring AG
Original Assignee
Universitaet Bern
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern, CSL Behring AG filed Critical Universitaet Bern
Application granted granted Critical
Publication of ES2660157T3 publication Critical patent/ES2660157T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES13708170.9T 2012-03-09 2013-03-08 Tratamiento de la mucositis con inmunoglobulina A Active ES2660157T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12158939.4A EP2636683A1 (en) 2012-03-09 2012-03-09 Treatment of mucositis with Immunoglobulin
EP12158939 2012-03-09
PCT/EP2013/054722 WO2013132063A1 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Publications (1)

Publication Number Publication Date
ES2660157T3 true ES2660157T3 (es) 2018-03-21

Family

ID=45808320

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13708170.9T Active ES2660157T3 (es) 2012-03-09 2013-03-08 Tratamiento de la mucositis con inmunoglobulina A

Country Status (10)

Country Link
US (1) US9546209B2 (enExample)
EP (2) EP2636683A1 (enExample)
JP (1) JP6238910B2 (enExample)
KR (1) KR102120620B1 (enExample)
CN (1) CN104254543B (enExample)
AU (1) AU2013201394B2 (enExample)
CA (1) CA2865810C (enExample)
DK (1) DK2822966T3 (enExample)
ES (1) ES2660157T3 (enExample)
WO (1) WO2013132063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
CA3043012A1 (en) 2016-11-10 2018-05-17 Becton, Dickinson And Company Timeline system for monitoring a culture media protocol
EP4662233A1 (en) * 2023-01-13 2025-12-17 Michael R. Simon Process for preparation of secretory iga and secretory igm and use thereof for treating necrotizing enterocolitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
HK1204629A1 (en) 2015-11-27
DK2822966T3 (en) 2018-02-26
AU2013201394A1 (en) 2013-09-26
WO2013132063A1 (en) 2013-09-12
CA2865810C (en) 2022-09-06
CN104254543B (zh) 2018-06-05
EP2822966A1 (en) 2015-01-14
AU2013201394B2 (en) 2015-09-03
JP2015513554A (ja) 2015-05-14
JP6238910B2 (ja) 2017-11-29
KR20140145587A (ko) 2014-12-23
US9546209B2 (en) 2017-01-17
CA2865810A1 (en) 2013-09-12
KR102120620B1 (ko) 2020-06-10
US20150030613A1 (en) 2015-01-29
CN104254543A (zh) 2014-12-31
EP2822966B1 (en) 2017-11-29
EP2636683A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
ES2983252T3 (es) Tratamiento de las infecciones polibacterianas
ES2529175T3 (es) Anticuerpo monoclonal humano contra la toxina alfa derivada de S. aureus y su uso en el tratamiento o la prevención de la formación de abscesos
ES2660157T3 (es) Tratamiento de la mucositis con inmunoglobulina A
AU2012236106B2 (en) Treatment for dermatological pathologies
KR20210072057A (ko) 항-황색포도상구균 항체의 조합
JP2025165988A (ja) プラスミノーゲンとの結合のための抗体
ES2985731T3 (es) Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R
HK1204629B (en) Treatment of mucositis with immunoglobulin a
US20170342136A1 (en) Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases
WO2018115048A1 (en) Methods for affecting salmonella infections
HK1236126A1 (en) Treatment of polybacterials infections
HK1187260A (en) Treatment for dermatological pathologies
BR112012002892A2 (pt) anticorpo monoclonal específico para a alfa-toxina de s. aureus, hibridoma, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo monoclonal, composição farmacêutica, uso de um anticorpo monoclonal e kit de teste para o diagnóstico de uma infecção de s. aureus